Matchpoint Therapeutics Raises $150 Million Series B for Immune-Drug Pipeline

Matchpoint Therapeutics, a Boston-based biotech developing small-molecule drugs that block protein-protein interactions, closed a $150 million Series B round. The company said the money will push its lead immunology and oncology programs toward clinical trials and add staff to its Cambridge labs. The raise follows a broader thaw in biotech funding after two slow years, but investors are still favoring later-stage bets over early science.

Source: Matchpoint Therapeutics Raises $150 Million Series B for Immune-Drug Pipeline — GlobeNewswire

A daily AI-made news meme from Jester · Oct 11, 2026.